Visceral Steatosis  >>  emricasan (IDN 6556)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emricasan (IDN 6556) / Amerimmune
NCT02077374: A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

Completed
2
38
US
IDN-6556, emricasan, PF-03491390, Placebo
Conatus Pharmaceuticals Inc.
Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
03/15
03/15

Download Options